Advisors Asset Management Inc. Has $650,000 Position in Becton, Dickinson and Company $BDX

Advisors Asset Management Inc. decreased its position in Becton, Dickinson and Company (NYSE:BDX) by 8.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,837 shares of the medical instruments supplier’s stock after selling 254 shares during the quarter. Advisors Asset Management Inc.’s holdings in Becton, Dickinson and Company were worth $650,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Saudi Central Bank acquired a new position in shares of Becton, Dickinson and Company during the 1st quarter worth about $26,000. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Becton, Dickinson and Company in the first quarter worth $27,000. REAP Financial Group LLC raised its stake in Becton, Dickinson and Company by 75.3% during the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 55 shares during the last quarter. Alpine Bank Wealth Management bought a new stake in Becton, Dickinson and Company in the 1st quarter valued at $29,000. Finally, Cornerstone Planning Group LLC grew its position in Becton, Dickinson and Company by 341.4% in the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 99 shares during the last quarter. 86.97% of the stock is owned by institutional investors.

Insider Activity at Becton, Dickinson and Company

In related news, Director Claire Fraser sold 863 shares of the firm’s stock in a transaction on Friday, August 8th. The stock was sold at an average price of $192.30, for a total transaction of $165,954.90. Following the sale, the director owned 23,143 shares of the company’s stock, valued at approximately $4,450,398.90. This trade represents a 3.59% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Michael David Garrison sold 1,185 shares of the company’s stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the transaction, the executive vice president owned 4,887 shares of the company’s stock, valued at $881,077.23. This trade represents a 19.52% decrease in their position. The disclosure for this sale can be found here. 0.36% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have commented on BDX shares. Wells Fargo & Company upped their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a report on Friday, August 8th. Morgan Stanley raised their target price on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Barclays lowered their price target on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating on the stock in a report on Tuesday, June 3rd. Piper Sandler reaffirmed a “neutral” rating and set a $200.00 price objective (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Finally, Wall Street Zen raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Four equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $211.44.

Becton, Dickinson and Company Trading Down 1.0%

Shares of NYSE BDX opened at $188.57 on Thursday. Becton, Dickinson and Company has a 1-year low of $163.33 and a 1-year high of $251.99. The company has a 50-day moving average of $185.95 and a two-hundred day moving average of $192.31. The company has a market cap of $54.05 billion, a PE ratio of 33.91, a P/E/G ratio of 1.42 and a beta of 0.27. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, beating analysts’ consensus estimates of $3.40 by $0.28. The firm had revenue of $5.51 billion for the quarter, compared to analyst estimates of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The business’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same period last year, the company earned $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, equities analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be given a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Monday, September 8th. Becton, Dickinson and Company’s payout ratio is presently 74.82%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.